Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec felis eros, feugiat a dolor non, lobortis hendrerit ipsum. Integer et efficitur arcu. Fusce semper mauris mauris, vestibulum scelerisque odio elementum imperdiet. Donec lobortis bibendum lectus id maximus. Etiam felis augue, pulvinar quis porttitor porttitor, dignissim in orci. Praesent in nulla sit amet tellus cursus feugiat sit amet eget eros. Ut in cursus libero. Phasellus ut turpis consectetur, bibendum lectus ut, faucibus purus.
Nullam et nisi est. Donec fermentum ultricies libero in cursus. Nulla facilisi. Etiam scelerisque mauris ac pretium eleifend. In hac habitasse platea dictumst. Vivamus vel nunc semper lorem facilisis maximus.
vancomycin – population pharmacokinetics meta-analysis
Population pharmacokinetics meta-analysis based on all available published studies and data collected during clinical practice to determine the optimised dosage regimen of vancomycin to be used in children less than 3 months of age.
GABA-3
Model-based bridging of clinical data for children from 3 months to < 3 years to simulate PK/PD, clinical efficacy and safety data of gabapentin in children from 3 years to less than 18 years of age in chronic pain.
Systematic review – Chiesi Farmaceutici SpA
A systematic review analysing the methods of treatment of sepsis and the factors causing antibiotic resistance in neonatal population is ongoing. The review is focused on the situation in five major European countries and results will been soon provided to the customer (Chiesi Farmaceutici SpA).